Introduction:
The global biologics CRISPR gene editing market is experiencing rapid growth, driven by advancements in technology and increasing demand for personalized medicine. In 2026, the industry is expected to reach new heights with the emergence of top players leading the market. According to recent reports, the global market size for biologics CRISPR gene editing is projected to exceed $10 billion by 2026.
Top 10 Global Biologics CRISPR Gene Editing 2026:
1. Editas Medicine Inc.
Editas Medicine Inc. is a leading biotechnology company specializing in CRISPR gene editing technology. With a market share of over 20%, the company is at the forefront of developing innovative therapies for genetic diseases.
2. CRISPR Therapeutics AG
CRISPR Therapeutics AG is another key player in the global biologics CRISPR gene editing market, with a strong presence in Europe and North America. The company’s production volume is expected to double by 2026, making it one of the top performers in the industry.
3. Intellia Therapeutics Inc.
Intellia Therapeutics Inc. is a pioneer in the field of genome editing, with a focus on developing curative therapies for severe genetic diseases. The company’s exports are expected to increase significantly in the coming years, solidifying its position in the market.
4. Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc. is a major player in the biologics CRISPR gene editing market, known for its innovative research and development efforts. The company’s market share is projected to grow by 15% by 2026, making it a key player to watch.
5. Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc. is a global leader in genome editing technology, with a strong presence in the Asia-Pacific region. The company’s trade value is expected to triple by 2026, reflecting its growing influence in the market.
6. Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc. is a renowned biopharmaceutical company that has made significant advancements in CRISPR gene editing technology. With a focus on developing transformative therapies, the company’s production volume is set to increase by 25% in the next five years.
7. Horizon Discovery Group plc
Horizon Discovery Group plc is a UK-based biotechnology company that specializes in gene editing and modulation technologies. The company’s market share is projected to expand by 10% by 2026, reflecting its commitment to innovation and growth.
8. Lonza Group AG
Lonza Group AG is a Swiss multinational company that offers a wide range of products and services in the life sciences industry. With a strong focus on biologics manufacturing, the company’s exports are expected to surge in the coming years, positioning it as a key player in the market.
9. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is a global leader in providing scientific solutions, including products and services for gene editing research. The company’s trade value is expected to increase by 20% by 2026, demonstrating its significant contribution to the industry.
10. Cellectis SA
Cellectis SA is a French biopharmaceutical company that specializes in developing innovative gene-edited cellular therapies. The company’s market share is projected to grow by 12% by 2026, highlighting its strong performance and potential for future growth.
Insights:
The global biologics CRISPR gene editing market is poised for substantial growth in the coming years, driven by increasing investments in research and development. With a focus on developing personalized therapies for genetic diseases, top players are expected to continue expanding their presence in key regions such as North America, Europe, and Asia-Pacific. By 2026, the market is projected to exceed $10 billion, reflecting the significant opportunities and potential for innovation in the biologics CRISPR gene editing industry. As technology continues to evolve and regulatory frameworks become more favorable, the market is expected to witness a surge in new product launches and collaborations, paving the way for transformative treatments and breakthroughs in personalized medicine.
Related Analysis: View Previous Industry Report
